COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update

被引:155
作者
Yang, Ian A. [1 ,2 ]
Browns, Juliet L. [3 ]
George, Johnson [4 ]
Jenkins, Sue [5 ,6 ]
McDonald, Christine F. [7 ,8 ]
McDonald, Vanessa M. [9 ,10 ]
Phillips, Kirsten [3 ]
Smith, Brian J. [11 ]
Zwar, Nicholas A. [12 ]
Dabscheck, Eli [13 ]
机构
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Prince Charles Hosp, Brisbane, Qld, Australia
[3] Lung Fdn Australia, COPD Natl Program, Brisbane, Qld, Australia
[4] Monash Univ, Ctr Med Use & Safety, Melbourne, Vic, Australia
[5] Curtin Univ, Perth, WA, Australia
[6] Sir Charles Gairdner Hosp, Perth, WA, Australia
[7] Austin Hosp, Melbourne, Vic, Australia
[8] Univ Melbourne, Melbourne, Vic, Australia
[9] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia
[10] John Hunter Hosp, Newcastle, NSW, Australia
[11] Queen Elizabeth Hosp, Adelaide, SA, Australia
[12] Univ New South Wales, Sydney, NSW, Australia
[13] Alfred Hlth, Melbourne, Vic, Australia
关键词
ACUTE EXACERBATIONS; COMORBIDITY; OUTCOMES; SOCIETY; QUALITY; ASTHMA; OXYGEN; GRADE; RISK;
D O I
10.5694/mja17.00686
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow Limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X pLan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis. Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of Life) and prevent deterioration (ie, prevent exacerbations and reduce decline). Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients. Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled corticosteroids) should be considered in a stepwise approach. Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly. Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations. A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management. Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression. Comorbidities of COPD require identification and appropriate management. Supportive, palliative and end-of-Life care are beneficial for patients with advanced disease. Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 61 条
[1]
COPDX: an update of guidelines for the management obstructive pulmonary disease with a review of recent [J].
Abramson, Michael J. ;
Crockett, Alan J. ;
Frith, Peter A. ;
McDonald, Christine F. .
MEDICAL JOURNAL OF AUSTRALIA, 2006, 184 (07) :342-345
[2]
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation [J].
Albert, Richard K. ;
Au, David H. ;
Blackford, Amanda L. ;
Casaburi, Richard ;
Cooper, J. Allen, Jr. ;
Criner, Gerard J. ;
Diaz, Philip ;
Fuhlbrigge, Anne L. ;
Gay, Steven E. ;
Kanner, Richard E. ;
MacIntyre, Neil ;
Martinez, Fernando J. ;
Panos, Ralph J. ;
Piantadosi, Steven ;
Sciurba, Frank ;
Shade, David ;
Stibolt, Thomas ;
Stoller, James K. ;
Wise, Robert ;
Yusen, Roger D. ;
Tonascia, James ;
Sternberg, Alice L. ;
Bailey, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (17) :1617-1627
[3]
Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD A Systematic Review and Meta-analysis [J].
Aleva, Floor E. ;
Voets, Lucas W. L. M. ;
Simons, Sami O. ;
de Mast, Quirijn ;
van der Ven, Andre J. A. M. ;
Heijdra, Yvonne F. .
CHEST, 2017, 151 (03) :544-554
[4]
Australian and New Zealand Pulmonary Rehabilitation Guidelines [J].
Alison, Jennifer A. ;
McKeough, Zoe J. ;
Johnston, Kylie ;
McNamara, Renae J. ;
Spencer, Lissa M. ;
Jenkins, Sue C. ;
Hill, Catherine J. ;
McDonald, Vanessa M. ;
Frith, Peter ;
Cafarella, Paul ;
Brooke, Michelle ;
Cameron-Tucker, Helen L. ;
Candy, Sarah ;
Cecins, Nola ;
Chan, Andrew S. L. ;
Dale, Marita T. ;
Dowman, Leona M. ;
Granger, Catherine ;
Halloran, Simon ;
Jung, Peter ;
Lee, Annemarie L. ;
Leung, Regina ;
Matulick, Tamara ;
Osadnik, Christian ;
Roberts, Mary ;
Walsh, James ;
Wootton, Sally ;
Holland, Anne E. .
RESPIROLOGY, 2017, 22 (04) :800-819
[5]
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations [J].
Andrews, Jeff ;
Guyatt, Gordon ;
Oxman, Andrew D. ;
Alderson, Phil ;
Dahm, Philipp ;
Falck-Ytter, Yngve ;
Nasser, Mona ;
Meerpohl, Joerg ;
Post, Piet N. ;
Kunz, Regina ;
Brozek, Jan ;
Vist, Gunn ;
Rind, David ;
Akl, Elie A. ;
Schuenemann, Holger J. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (07) :719-725
[6]
[Anonymous], 2006, COCHRANE DATABASE SY
[7]
[Anonymous], COCHRANE DATABASE SY
[8]
[Anonymous], 2015, AUSTR IMM HDB
[9]
[Anonymous], 2017, GLOB STRAT DIAGN MAN
[10]
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001288